Description
The skeptic noted that CD38 is expressed in multiple cell types and NAD+ depletion occurs through various pathways including PARP activation. Establishing causality is essential for validating senescent cells as therapeutic targets.
Source: Debate session sess_SDA-2026-04-01-gap-013 (Analysis: SDA-2026-04-01-gap-013)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:55.374183+00:00”, “resolution_summary”: “Resolved by hypothesis h-var-f40275ceb0: CD38 Inhibition to Prevent NAD+ Depletion and Restore Cellular Bioenergetics in Age-Related Metabolic Dysfunction. Supporting evidence includes debate sess_SDA-2026-04-12-gap-debate-20260410-112842-e2dec0d7.”, “match_counts”: {“hypothesis_matches”: 4, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-var-f40275ceb0”, “title”: “CD38 Inhibition to Prevent NAD+ Depletion and Restore Cellular Bioenergetics in Age-Related Metabolic Dysfunction”, “score”: 0.366, “reason”: “8 token overlaps; entity overlap: cd38, nad”, “analysis_id”: “SDA-2026-04-16-frontier-metabolomics-f03b09d9”, “target_gene”: “CD38, SIRT1/3”, “target_pathway”: “NAD+ salvage/consumption pathway”, “disease”: “metabolomics”, “composite_score”: 0.38, “confidence_score”: 0.258, “status”: “proposed”, “pubmed_evidence_ids”: [“23974067”, “25416150”, “29198525”, “31477785”]}, {“id”: “h-var-de3e3c7494”, “title”: “CD38 Inhibition to Preserve NAD+ Pools and Prevent PARP1-Mediated Metabolic Dysfunction”, “score”: 0.349, “reason”: “7 token overlaps; entity overlap: cd38, nad”, “analysis_id”: “SDA-2026-04-16-frontier-metabolomics-f03b09d9”, “target_gene”: “CD38, PARP1, SIRT1/3”, “target_pathway”: “NAD+ metabolism, CD38-NADase pathway”, “disease”: “metabolomics”, “composite_score”: 0.38, “confidence_score”: 0.258, “status”: “proposed”, “pubmed_evidence_ids”: [“23974067”, “25416150”, “29198525”, “31477785”]}, {“id”: “h-241752cd”, “title”: “CD38 Inhibition for NAD+ Restoration and Microglial Senescence Prevention”, “score”: 0.342, “reason”: “4 token overlaps; entity overlap: cd38, nad”, “analysis_id”: “SDA-2026-04-17-gap-microglial-subtypes-pharmaco-20260417000001”, “target_gene”: “CD38”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.575, “confidence_score”: 0.55, “status”: “proposed”, “pubmed_evidence_ids”: [“29894451”, “30642922”, “30742095”, “EMBRACE trial”]}, {“id”: “h-cb833ed8”, “title”: “Senescence-Activated NAD+ Depletion Rescue”, “score”: 0.326, “reason”: “17 token overlaps; entity overlap: cd38, nad”, “analysis_id”: “sda-2026-04-01-gap-013”, “target_gene”: “CD38/NAMPT”, “target_pathway”: “Cellular senescence / SASP signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.755221, “confidence_score”: 0.6, “status”: “promoted”, “pubmed_evidence_ids”: [“29234567”, “31456890”, “33567890”, “35789234”, “37567234”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112842-e2dec0d7”, “title”: “The debate proposed bioenergetic gradients drive transfer but didn’t identify the specific molecular sensors or trafficking machinery that determines which neurons receive mitochondria. Understanding these mechanisms is essential for therapeutic targeting.\n\nSource: Debate session sess_SDA-2026-04-01-gap-v2-89432b95 (Analysis: SDA-2026-04-01-gap-v2-89432b95)”, “score”: 0.369, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112842-e2dec0d7”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-debate-20260410-112951-80857f4e”, “title”: “The debate revealed conflicting evidence about whether HCN1 downregulation drives neuronal death or represents a protective response to excessive excitation. This causality question is critical for determining whether HCN1 enhancement would be therapeutic or harmful.\n\nSource: Debate session sess_SDA-2026-04-01-gap-004 (Analysis: SDA-2026-04-01-gap-004)”, “score”: 0.359, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-12-gap-debate-20260410-112951-80857f4e”, “quality_score”: 0.93, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-01-gap-010”, “title”: “What are the mechanisms underlying apoe4 structural biology and therapeutic targeting strategies?”, “score”: 0.34, “reason”: “4 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-01-gap-010”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: “SDA-2026-04-01-gap-010”, “target_artifact_type”: “analysis”}, {“id”: “sess_SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e_20260416-135601”, “title”: “The skeptic raised evidence that APOE4 carriers show enhanced cholesterol synthesis, suggesting the lipid binding deficit may be compensatory rather than harmful. This fundamental mechanistic question affects all lipid-based therapeutic approaches.\n\nSource: Debate session sess_SDA-2026-04-01-gap-auto-fd6b1635d9 (Analysis: SDA-2026-04-01-gap-auto-fd6b1635d9)”, “score”: 0.339, “reason”: “7 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e”, “quality_score”: 0.71, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-01-gap-013”, “title”: “What are the mechanisms underlying senolytic therapy for age-related neurodegeneration?”, “score”: 0.333, “reason”: “3 token overlaps; entity overlap: sda-2026-04-01-”, “analysis_id”: “SDA-2026-04-01-gap-013”, “quality_score”: 0.92, “status”: “completed”, “target_artifact_id”: “SDA-2026-04-01-gap-013”, “target_artifact_type”: “analysis”}], “paper_matches”: []}